Comparison of Efficacy and Safety Among Dabigatran, Rivaroxaban, and Apixaban in Non-Valvular Atrial Fibrillation

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 3672 participants.

Also called NCT02666157

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 3,672 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT02666157
Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Taiwan (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT02666157. Randomized; no masking; primary purpose treatment. Start 2016-01 (registry gives no type); primary completion 2018-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Comparison of Efficacy and Safety Among Dabigatran, Rivaroxaban, and Apixaban in Non-Valvular Atrial Fibrillation
Acronym
DARING-AF
Intervention (Drug)
Dabigatran etexilate
Intervention (Drug)
Rivaroxaban
Intervention (Drug)
Apixaban
Lead sponsor
National Cheng-Kung University Hospital (class: other)
Collaborator
Tainan Municipal Hospital (class: other)
Collaborator
E-DA Hospital (class: other)
Collaborator
National Cheng-Kung University Hospital Dou-Liou Branch (class: not stated)
Collaborator
Ministry of Health and Welfare, Taiwan (class: other government)

Record details

Record id
cardio:ct-nct02666157
Content hash
63b351f8a04c86fb1b0d40118b19f9126b1c8677b72362b9d9d4b1d0a534d13a